Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919552 | 0.86 | MAPK1 (0.62) | MAPK1KMT2ARAB9APOLB | |
| SCHEMBL27086721 | 0.86 | MAPK1 (0.62) | MAPK1KMT2ARAB9APOLB | |
| SCHEMBL25152979 | 0.86 | MAPK1 (0.62) | MAPK1KMT2ARAB9APOLB | |
| SCHEMBL8939993 | 0.85 | ALDH1A1 (0.64) | MAPK1CASP3ALDH1A1KMT2AMAPT | |
| SCHEMBL29162584 | 0.82 | MAPK1 (0.51) | MAPK1CASP3ALDH1A1GAAKMT2A | |
| SCHEMBL30726156 | 0.82 | MAPK1 (0.51) | MAPK1CASP3ALDH1A1GAAKMT2A | |
| SCHEMBL29162583 | 0.82 | MAPK1 (0.51) | MAPK1CASP3ALDH1A1GAAKMT2A | |
| SCHEMBL17595505 | 0.82 | MAPK1 (0.59) | MAPK1CASP3ALDH1A1KMT2AMAPT | |
| SCHEMBL7163322 | 0.81 | MAPK1 (0.59) | MAPK1ALDH1A1MAPTPOLB | |
| SCHEMBL6153732 | 0.80 | MAPK1 (0.58) | MAPK1CASP3ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | MAPK1 115/4885CASP3 600/4885ALDH1A1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.